Related Experiment Videos
Hemochromatosis gene variants in patients with cardiomyopathy
A C Pereira1, M A Cuoco, G F Mota
1Heart Institute (InCor) and Internal Medicine Department, São Paulo University Medical School, São Paulo, Brazil.
Insights
Genetic variations in the HFE gene, specifically the C282Y mutation, are linked to a higher risk of ischemic cardiomyopathy. This finding suggests a potential role for genetic screening in predicting heart disease risk.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Iron depletion has been hypothesized to protect against ischemic heart disease.
- Previous population studies yielded conflicting results.
- The association between iron-related genetic factors and heart failure due to cardiomyopathy remains understudied.
Purpose of the Study:
- To investigate the distribution of hemochromatosis-related mutations in patients with heart failure.
- To determine if specific HFE gene mutations are associated with ischemic cardiomyopathy.
Main Methods:
- Studied 319 patients with heart failure due to cardiomyopathy of various etiologies.
- Analyzed the genotypic distribution of hemochromatosis-related mutations, including C282Y and D63.
- Employed multiple logistic regression models adjusted for demographic and clinical factors.
Main Results:
- A significantly higher prevalence of C282Y heterozygotes was observed in patients with ischemic cardiomyopathy compared to nonischemic etiologies (p = 0.0036).
- The D63 mutation frequency did not differ significantly between the groups.
- The C282Y mutation showed a strong association with ischemic cardiomyopathy (OR 6.64, 95% CI 1.71-25.73) after adjustments.
Conclusions:
- Genetic variation in the HFE gene, particularly the C282Y mutation, is associated with ischemic cardiomyopathy in the studied cohort.
- This association warrants further investigation for its potential as a prognostic marker in ischemic heart disease.
Abstract:
Iron depletion was suggested to be protective against the development of ischemic heart disease. Population studies have led to conflicting results, and such an association has not been addressed in patients with heart failure due to cardiomyopathy. We studied the distribution of hemochromatosis-related mutations in 319 patients with heart failure due to cardiomyopathy of different etiologies. The genotypic distribution showed a significantly higher prevalence of heterozygotes for the C282Y mutation in patients with ischemic cardiomyopathy than in patients with cardiomyopathy of nonischemic etiologies (p = 0.0036). The frequency of the D63 mutation was not significantly different between ischemic versus nonischemic groups. In multiple logistic regression models adjusted for age, sex, ethnicity, and different degrees of disease progression, there was a strong and significant association of the C282Y mutation with ischemic cardiomyopathy compared with the nonischemic group (odds ratio 6.64, 95% confidence interval 1.71 to 25.73, after adjustment). In our sample, genetic variation in the HFE gene was associated with ischemic cardiomyopathy. Such association merits further study regarding its value as a prognostic marker in patients with ischemic heart disease.